Cargando…
Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients
BACKGROUND: The safety of gadolinium‐based contrast agents is of fundamental importance. PURPOSE: To determine the frequency and severity of immediate‐type adverse reactions to approved doses of gadoteridol in patients referred for routine gadoteridol‐enhanced MRI in actual clinical practice setting...
Autores principales: | Cho, Sung Bum, Lee, A‐Leum, Chang, Hyuk Won, Kim, Kyeong Ah, Yoo, Won Jong, Yeom, Jeong A., Rho, Myung Ho, Kim, Sung Jin, Lim, Yun‐jung, Han, Miran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027821/ https://www.ncbi.nlm.nih.gov/pubmed/31663202 http://dx.doi.org/10.1002/jmri.26940 |
Ejemplares similares
-
Measurement of lifetimes in $^{62,64}$Fe,$^{61,63}$Co , and $^{59}$Mn
por: Klintefjord, M, et al.
Publicado: (2017) -
Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger
por: Shah, Chetan C., et al.
Publicado: (2021) -
The MRI Contrast Agent Gadoteridol Enhances Distribution of rAAV1 in the Rat Hippocampus
por: Hullinger, Rikki, et al.
Publicado: (2013) -
Two-colour serial femtosecond crystallography dataset from gadoteridol-derivatized lysozyme for MAD phasing
por: Gorel, Alexander, et al.
Publicado: (2017) -
The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis
por: Kuhn, Matthew J., et al.
Publicado: (2021)